Updated results of the first in man evaluation of the histone deacetylase (HDAC) inhibitor, PXD101 in cancer patients (pts).

被引：0
|
作者：
de Bono, JS
Steele, N
Vidal, L
Reid, A
Marriott, C
Tjornelund, J
Shaw, H
Plumb, J
Molife, R
Morrison, R
Fong, P
Buhl-Jensen, P
Rasmussen, A
Evans, TRJ
机构：
[1] Royal Marsden NHS Trust, Sutton, Surrey, England
[2] Beatson Oncol Ctr, Glasgow, Lanark, Scotland
[3] TopoTargets, Copenhagen, Denmark
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：9121S / 9121S
页数：1
相关论文
共 50 条
  • [1] Activity of the histone deacetylase (HDAC) inhibitor PXD101 in preclinical prostate cancer studies
    Jeffers, M.
    Qian, X.
    Mills, E.
    LaRochelle, W.
    Lichenstein, H.
    Ara, G.
    EJC SUPPLEMENTS, 2006, 4 (12): : 109 - 109
  • [2] Activity of the histone deacetylase (HDAC) inhibitor PXD101 in preclinical ovarian cancer studies.
    Qian, XZ
    LaRochelle, WJ
    Ara, G
    Wu, F
    Petersen, KD
    Thougaard, A
    Sehested, M
    Lichenstein, HS
    Jeffers, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9080S - 9080S
  • [3] Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment
    Lin, Shu-Fu
    Lin, Jen-Der
    Chou, Ting-Chao
    Huang, Yu-Yao
    Wong, Richard J.
    PLOS ONE, 2013, 8 (10):
  • [4] A phase I study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced hematological tumors
    Hansen, M
    Gimsing, P
    Rasmussen, A
    Jensen, PB
    Knudsen, LM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 225S - 225S
  • [5] Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
    Qian, Xiaozhong
    LaRochelle, William J.
    Ara, Gulshan
    Wu, Frank
    Petersen, Kamille Dumong
    Thougaard, Annemette
    Sehested, Maxwell
    Lichenstein, Henri S.
    Jeffers, Michael
    MOLECULAR CANCER THERAPEUTICS, 2006, 5 (08) : 2086 - 2095
  • [6] Effect of the histone deacetylase (HDAC) inhibitor PXD101 on the human colon carcinoma cell line FET
    McArdle, Jessica K.
    Brattain, Michael
    Howell, Gillian
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 757 - 757
  • [7] Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer
    Qian, Xiaozhong
    Ara, Gulshan
    Mills, Evan
    LaRochelle, William J.
    Lichenstein, Henri S.
    Jeffers, Michael
    INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (06) : 1400 - 1410
  • [8] A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours.
    Steele, N
    Vidal, L
    Plumb, J
    Attard, G
    Rasmussen, A
    Buhl-Jensen, P
    Brown, R
    Blagden, S
    Evans, J
    de Bono, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 200S - 200S
  • [9] Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)
    N. L. Steele
    J. A. Plumb
    L. Vidal
    J. Tjørnelund
    P. Knoblauch
    P. Buhl-Jensen
    R. Molife
    R. Brown
    J. S. de Bono
    T. R. J. Evans
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1273 - 1279
  • [10] Plasma and cerobrospinal fluid (CSF) pharmacokinetics of the histone deacetylase (HDAC) inhibitor, PXD101, in non-human primates
    Warren, Katherine E.
    McCully, Cindy M.
    Dvinge, Henrik
    Sehested, Maxwell
    Tjornelund, Jette
    Lichenstein, Henri S.
    Balis, Frank M.
    CANCER RESEARCH, 2006, 66 (08)
12345